Skip to Main Content

Amer Zeidan, MBBS

Associate Professor of Internal Medicine (Hematology)

Contact Information

Amer Zeidan, MBBS

Patient Care Location

  • Smilow Cancer Hospital at Yale New Haven
    35 Park Street, Ste NP-7
    New Haven, CT, 06511

Mailing Address

  • Hematology

    333 Cedar Street, PO Box 208028

    New Haven, CT, 06520-8028

    United States

Amer Zeidan
DownloadHi-Res Photo



Amer Zeidan, MBBS, MHS is an an Assistant Professor of Medicine (Hematology) at Yale University. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, Jordan before completing his internal medicine residency at Rochester General Hospital, Rochester, NY.

Dr. Zeidan specializes in the management of blood cancers especially MDS and acute myeloid leukemia (AML). The focus of his clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.

The second area of research interest for Dr. Zeidan is effectiveness and outcomes research in hematologic malignancies; a type of research that evaluates how much benefit do patients achieve from existing treatments at the real-world community level in comparison to what is seen in the controlled clinical trials setting. Using large databases, Dr. Zeidan and his colleagues confirmed the clinical benefits of hypomethylating agents (azacitidine and decitabine), lenalidomide and iron chelation therapy in patients with MDS at the population level. Dr. Zeidan conducts this research within the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University. In addition, Dr. Zeidan used clinical databases to understand how well do the current risk stratification models that are used in the clinic to counsel patients with MDS and make treatment recommendations work in the real-world patient level.

Dr. Zeidan has been awarded the American Society of Clinical Oncology Young Investigator Award (ASCO YIA), the Aplastic Anemia and MDS International Foundation (AAMDSIF)/Ed Evan’s Foundation- MDS Clinical Research Consortium Fellowship award, The TITO BASTIANELLO Young Investigator Award and multiple abstract achievement and travel awards. Dr. Zeidan has presented his research in multiple national and international meetings and is an author on more than 90 peer-reviewed publications.

Education & Training

  • MBBS
    University of Jordan (2001)
  • Fellowship
    Johns Hopkins Hospital
  • Internship
    Rochester General Hospital

Departments & Organizations